Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
Ines Vaz-Luis, Prudence A Francis, Antonio Di Meglio, Vered Stearns
Am Soc Clin Oncol Educ Book | Published : 2021
More than 90% of women with newly diagnosed breast cancer present with stage I to III disease and, with optimal multidisciplinary therapy, are likely to survive their disease. Of these patients, 70% are hormone receptor-positive and candidates for adjuvant endocrine therapy. The adoption of cumulatively better adjuvant treatments contributed to improved outcomes in patients with hormone receptor-positive, early-stage breast cancer. Premenopausal women with hormone receptor-positive breast cancer often present with complex disease and have inferior survival outcomes compared with their postmenopausal counterparts. Risk stratification strategies, including classic clinicopathologic features an..View full abstract